April 17 (Reuters) - Sage Therapeutics ( SAGE ) said on
Wednesday its experimental drug to treat patients with mild
cognitive impairment due to Parkinson's disease failed to show
significant improvement in a mid-stage study.
(Reporting by Mariam Sunny in Bengaluru)